Teruisi Pharma’s TRS005 Receives Support for Breakthrough Designation in China for CD20-Positive Lymphoma
The Center for Drug Evaluation (CDE) in China has signaled that Teruisi Pharma’s antibody drug...
Cancer
Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma
The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...
GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a...
BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...
Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...
Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...
Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...
Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...
Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...
KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma
Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...
Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...
Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...
Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...
Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication
Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA)...
Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial
Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug...
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Bio-Thera Solutions Gets Green Light for Phase Ib/II Study of ADC BAT8008 in Advanced Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received approval from the National...
Betta Pharmaceuticals’ Ensartinib Accepted for FDA Review for First-Line ALK+ NSCLC Treatment
Betta Pharmaceuticals (SHE: 300558), a pharmaceutical company based in China, has announced that the market...